Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Recursion Pharmaceuticals
Biotech
Recursion streamlines pipeline following merger with Exscientia
Evidently in the mood for spring cleaning, Recursion is clearing out part of its pipeline as it narrows its focus on oncology and rare diseases.
Fraiser Kansteiner
May 5, 2025 11:00am
Former FDA deputy joins AI biotech's board—Chutes & Ladders
Mar 21, 2025 8:30am
Altitude sources funding for biotechs concerned about NIH grants
Feb 19, 2025 1:00pm
Ovid pauses ph. 2 plans for ROCK2 inhibitor to mull rival's data
Nov 13, 2024 8:15am
Recursion's brain disease trial shows scant evidence of efficacy
Sep 3, 2024 10:30am
After a tough year, Exscientia folds into Recursion
Aug 8, 2024 8:54am
